Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Off-label use of Psychotropic Medications in Preschool Children with Attention-deficit Hyperactivity Disorder

주의력결핍 과잉행동장애에서 허가 초과 약물 처방 : 학령전기 아동 중심으로

  • Kim, Eui-Jung (Department of Psychiatry, Ewha Womans University School of Medicine)
  • 김의정 (이화여자대학교 의학전문대학원 정신과학교실)
  • Received : 2011.05.25
  • Accepted : 2011.06.17
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder with an onset of symptoms before 7 years of age, often starting as early as the preschool years. The off-label use of methylphenidate (MPH) for 3- to 6-year-old preschool children with ADHD is being more common, although MPH is not licensed for use in children younger than age 6 years, in most countries. Despite the limited data, the review of the literature suggests that MPH meets evidence based criteria as beneficial and safe for carefully diagnosed ADHD preschool children. Carefully monitored administration of evidence-based psychotropic medication in preschool children with ADHD may be indicated if psychosocial treatments are ineffective.

Keywords

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text revision (DSM-IV-TR). Washington DC: American Psychiatric Press;2000.
  2. Lavine JV, Gibbons RD, Christoffel KK, Arend R, Rosenbaum D, Binns H, et al. Prevalence rates and correlates of psychiatric disorders among preschool children. J Am Acad Child Adolesc Psychiatry 1996;35:204-214. https://doi.org/10.1097/00004583-199602000-00014
  3. Dupaul GJ, McGoey KE, Eckert TL, Van Brakle J. Preschool children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2001;40:508-515. https://doi.org/10.1097/00004583-200105000-00009
  4. Lahey BB, Pelham WE, Loney J, Kipp H, Ehrhardt A, Lee SS et al. Three-year predictive validity of DSM-IV attention deficit hyperactivity disorder in children diagnosed at 4-6 years of age. Am J Psy-chiatry 2004;161:2014-2020. https://doi.org/10.1176/appi.ajp.161.11.2014
  5. Lahey BB, Pelham WE, Stein MA, Loney J, Trapani C, Nugent K et al. validity of DSM-IV attention deficit hyperactivity disorder for younger children. J Am Acad Child Adolesc Psychiatry 1998;37: 695-702. https://doi.org/10.1097/00004583-199807000-00008
  6. Pierce EW, Ewing LJ, Campbell SB. Diagnostic status and symptomatic behavior of hard-to-manage preschool children in middle childhood and early adolescence. J Clin Child Psychol 1998;28:44-57.
  7. McGee R, Prior M, Williams S. The long-term significance of tea-cher-rated hyperactivity and reading ability in childhood: findings from two longitudinal stidies. J Child Psychol Psychiatry 2002;43: 1004-1017. https://doi.org/10.1111/1469-7610.00228
  8. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36(10 Suppl):85S-121S. https://doi.org/10.1097/00004583-199710001-00007
  9. Offson M, Marcus SC, Weissman MM, Jensen PS. NAtional ternds in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002;41:514-521. https://doi.org/10.1097/00004583-200205000-00008
  10. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283:1025-1030. https://doi.org/10.1001/jama.283.8.1025
  11. Zuveska SH, Vitiello B, Norquist GS. Recent treds in stimulant me-dication use among U.S. children. Am J Psychiatry 2006;163:579-585. https://doi.org/10.1176/appi.ajp.163.4.579
  12. US Food and Drug Administration. Medication guide: Ritalin. [accessed on 15 Feb 2011]. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089090.pdf.
  13. Korean Food and Drug Administration. Medications that are prohibited in children and adolescents. [accessed on 15 Feb 2011]. Available from http://ezdrug.kfda.go.kr/kfda2.
  14. Greenhill LL, Posner K, Vaughan BS, Kratochvil CJ. attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatr Clin N Am 2008;17:347-366. https://doi.org/10.1016/j.chc.2007.11.004
  15. Schliefer M, Weiss G, Cohen N, Elman M, Cvejic H, Kruger E. Hyperactivity in preschoolers and the effect of methylphenidate. Am J Orthopsychiatry 1975;45:38-50. https://doi.org/10.1111/j.1939-0025.1975.tb01164.x
  16. Conners CK. Controlled trial of methylphenidate in preschool children with minimal brain dysfunction. Int J Ment Health 1975;4:61-74. https://doi.org/10.1080/00207411.1975.11448675
  17. Cunningham CE, Siegel LS, Offord DR. A developmental dose-response analysis of the effects of methylphenidate on the peer interactions of attention deficit disordered boys. J Child Psychol Psychiatry 1985;26:955-971. https://doi.org/10.1111/j.1469-7610.1985.tb00609.x
  18. Barkley RA, Karlsson J, Strzelecki E, Murphy JV. Effects of age and Ritalin dosage on the mother-child interactions of hyperactive children. J Consult Clin Psychol 1984;52:750-758. https://doi.org/10.1037/0022-006X.52.5.750
  19. Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry 1988;27:336-341. https://doi.org/10.1097/00004583-198805000-00012
  20. Mayes SD, Crites DL, Bixler EO, Humphrey FJ 2nd, Mattison RE. Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status. Dev Med Child Neurol 1994;36:1099-1107.
  21. Musten LM, Firestone P, Pisterman S, Bennett S, Mercer JJ. Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions. Am Acad Child Adolesc Psychiatry 1997; 36:1407-1415. https://doi.org/10.1097/00004583-199710000-00023
  22. Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 1999;38:805-812. https://doi.org/10.1097/00004583-199907000-00009
  23. Short EJ, Manos MJ, Findling RL, Schubel EA. A prospective study of stimulant response in preschool children: insights from ROC analyses. J Am Acad Child Adolesc Psychiatry 2004;43:251-259. https://doi.org/10.1097/00004583-200403000-00005
  24. Firestone P, Musten LM, Pisterman S, Mercer J, Bennett S. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1998;8:13-25. https://doi.org/10.1089/cap.1998.8.13
  25. Greenhill LL, Kollins S, Abikoff H, McCracken JT, Riddle MA, Swanson J, et al. Efficacy and Safety of immediate-release methylphenidate for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45:1284-1293. https://doi.org/10.1097/01.chi.0000235077.32661.61
  26. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, et al. Safety and tolerability of methylpheniate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45: 1294-1313. https://doi.org/10.1097/01.chi.0000235082.63156.27
  27. Vitiello B, Abikoff H, Chuang SZ, Kollins SH, McCracken JT, Riddle MA, et al. Effectiveness of methylphenidate in the 10 month continuation phase of the preschoolers with attention deficit/hyperactivity disorder treatment study (PATS). J Child Adolesc Psychopharmacol 2007;17:593-604. https://doi.org/10.1089/cap.2007.0058
  28. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004;113:762-769. https://doi.org/10.1542/peds.113.4.762
  29. Wigal SB, Gupta S, Greenhill L, Posner K, Lerner M, Steinhoff K, et al. Pharmacokinetics of methylphenidate in preschoolers with attention- deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:153-164. https://doi.org/10.1089/cap.2007.0043
  30. Maayan L, Paykina N, Fried J, Strauss T, Gugga SS, Greenhill L. The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate. J Child Adolesc Psychopharmacol 2009;19:147-153. https://doi.org/10.1089/cap.2008.053
  31. Kratochvil CJ, Vaughan BS, Mayfield-Jorgensen ML, March JS, Kol-lins SH, Murray DW, et al. A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:175-185. https://doi.org/10.1089/cap.2006.0143
  32. Ghuman JK, Aman MG, Ghuman HS, Reichenbacher T, Gelenberg A, Wright R, et al. Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19:155-166. https://doi.org/10.1089/cap.2008.054
  33. Cesena M, Lee DO, Cebollero AM, Steingard RJ. Case study: behavioral symptoms of pediatric HIV-1 encephalopathy successfully treated with clonidine. J Am Acad Child Adolesc Psychiatry 1995; 34:302-306. https://doi.org/10.1097/00004583-199503000-00014
  34. Lee BJ. Clinical experience with guanfacine in 2-and 3-year-old children with attention-deficit hyperactivity disorder. Infant Mental Health 1997;18:300-305. https://doi.org/10.1002/(SICI)1097-0355(199723)18:3<300::AID-IMHJ6>3.0.CO;2-Q
  35. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1551-1559. https://doi.org/10.1097/00004583-199912000-00017
  36. Scahill L, Barloon L, Farkas L. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Nurs 1999;12:168-173. https://doi.org/10.1111/j.1744-6171.1999.tb00065.x
  37. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, et al. The Texas Children's Medication Algorithm Project : revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-657.
  38. Campbell NB, Tamburrino MB, Evans CL, Franco KN. Fluoxetine for ADHD in a young child. J Am Acad Child Adolesc Psychiatry 1995;34:1259-1260. https://doi.org/10.1097/00004583-199510000-00008
  39. Riddle MA, Kastelic EA, Frosch E. Pediatric psychopharmacology. J Child Psychol Psychiatry 2001;42:73-90. https://doi.org/10.1111/1469-7610.00703
  40. Connor DF. Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treat-ment. J Dev Behav Pediatr 2002;23(1 Suppl):S1-S9. https://doi.org/10.1097/00004703-200202001-00002
  41. Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA, Lie-berman AF, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007;46:1532-1572. https://doi.org/10.1097/chi.0b013e3181570d9e
  42. Vaughan BS, March JS, Kratochvil CJ. The evidence-based pharmacological treatment of paediatric ADHD. Int J Neuropsychopharmacol; 2011. p.1-13. https://doi.org/10.1017/S1461145711000812
  43. Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psy-chopharmacol 2008;18:413-447. https://doi.org/10.1089/cap.2008.022